\n <\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
\n <\/ul>\n
\n VAP reduction
\n 67 percent reduction
\n
\n Ventilator-associated pneumonia cases at Inova using ENvue navigation
\n
\n <\/p>\n
\n Placements analyzed
\n 531 placements
\n
\n Consecutive ENvue-guided feeding tube placements in first year
\n
\n <\/p>\n
\n Airway misplacement rate (blind)
\n 1.2 to 3.2 percent
\n
\n Estimated inadvertent airway placement using blind techniques from prior studies
\n
\n <\/p>\n
\n Hospital cost savings
\n Over $1.5 million
\n
\n Estimated VAP-related hospital costs avoided in year one
\n
\n <\/p>\n
\n Nursing hours saved
\n Over 350 hours
\n
\n Nursing hours saved in first year using ENvue platform
\n
\n <\/p>\n
\n Repeat imaging reduction
\n 20% decrease
\n
\n Decrease in repeat imaging to confirm tube placement
\n
\n <\/p>\n
\n Fewer X-rays
\n 20 percent fewer
\n
\n Reduction in X-rays to confirm feeding tube placement
\n
\n <\/p>\n
\n Aspiration pneumonia reduction
\n 20 percent reduction
\n
\n Reduction in hospital-acquired aspiration pneumonia
\n
\n <\/p>\n
\n $0.9044
\n Last Close
\n <\/p>\n
\n Volume
\n Volume 102,603<\/b> is well below 20-day average 710,208<\/b> (relative volume 0.14x<\/b>).
\n
\n low
\n
\n <\/p>\n
\n Technical
\n Shares trade below 200-day MA of 1.95<\/b> with current price at 0.905<\/b>, near the 52-week low of 0.84<\/b> and far below the 52-week high of 6.09<\/b>.
\n <\/p>\n
No peer stocks were flagged in the momentum scanner and no same-day peer headlines were provided, indicating this news is being absorbed as company-specific rather than part of a broader medical device move.<\/p>\n
\n
<\/p>\n
\n Date
\n Event
\n Sentiment
\n Move
\n Catalyst
\n <\/tr>\n
\n
\n
\n
<\/p>\n
<\/p>\n
\n
\n Conference showcasing<\/a>
\n \n <\/td>\n
<\/p>\n
\n Positive \n <\/td>\n
\n
<\/p>\n
\n -7.9% \n <\/td>\n
<\/p>\n
\n
\n
\n
\n Showcasing ENvue Navigation Platform at AACN NTI 2026 conference. \n <\/td>\n
\n <\/tr>\n
\n
<\/p>\n
<\/p>\n
\n
\n Contract renewal<\/a>
\n \n <\/td>\n
<\/p>\n
\n Positive \n <\/td>\n
\n
<\/p>\n
\n +1.6% \n <\/td>\n
<\/p>\n
\n
\n Three-year contract renewal making platform standard of care at 12 hospitals. \n <\/td>\n
\n <\/tr>\n
\n
<\/p>\n
<\/p>\n
\n
\n IP expansion<\/a>
\n \n <\/td>\n
<\/p>\n
\n Positive \n <\/td>\n
\n
<\/p>\n
\n -9.8% \n <\/td>\n
<\/p>\n
\n
\n
\n
\n USPTO Notice of Allowance for ultrasound-enhanced cannabinoid delivery patent. \n <\/td>\n
\n <\/tr>\n
\n
<\/p>\n
<\/p>\n
\n
\n GPO agreement renewal<\/a>
\n \n <\/td>\n
<\/p>\n
\n Positive \n <\/td>\n
\n
<\/p>\n
\n +5.6% \n <\/td>\n
<\/p>\n
\n
\n Three-year GPO purchasing renewal covering over 90 hospitals in 17 states. \n <\/td>\n
\n <\/tr>\n
\n
<\/p>\n
<\/p>\n
\n
\n New hospital customer<\/a>
\n \n <\/td>\n
<\/p>\n
\n Positive \n <\/td>\n
\n
<\/p>\n
\n -4.4% \n <\/td>\n
<\/p>\n
\n
\n
\n
\n Announcement of 40th U.S. hospital customer adopting ENvue platform. \n <\/td>\n
\n <\/tr>\n
\n
\n
<\/p>\n
Pattern Detected<\/p>\n
Recent positive operational and commercial updates have often met mixed to negative price reactions, with more divergence than alignment between good news and short-term moves.<\/p>\n
Recent Company History<\/p>\n
Over the past few months, ENvue reported several commercial milestones, including a three-year contract renewal across 12 hospitals<\/b> and a separate GPO purchasing renewal covering over 90 hospitals<\/b> through 2028<\/b>. It also highlighted its 40th U.S. hospital<\/b> customer and secured a USPTO Notice of Allowance for an ultrasound-enhanced cannabinoid delivery patent. Despite largely positive operational developments, price reactions have been inconsistent, suggesting that strong news has not reliably translated into sustained upside ahead of today\u2019s safety-and-cost outcome publication.<\/p>\n
\n This announcement highlights independently validated benefits of the ENvue Navigation Platform, including a 67 percent<\/b> reduction in ventilator-associated pneumonia, over 350<\/b> nursing hours saved, and more than $1.5 million<\/b> in estimated cost avoidance in year one. In context of recent contract renewals and growing hospital adoption, the study strengthens the clinical and economic case presented in prior news. Investors may watch for additional health system deployments, reimbursement dynamics, and any future updates on clinical outcomes and utilization trends.
\n <\/p>\n
\n
\n intensive care units
\n
\n medical
\n
\n
<\/p>\n
“one of the most consequential procedural risks in hospital intensive care units: feeding tube misplacement.”<\/p>\n
A hospital area that provides round\u2011the\u2011clock monitoring and life\u2011support for patients with life\u2011threatening conditions, staffed with specialized equipment and nurses and doctors trained for critical care. For investors, ICU capacity and utilization act like an indicator of strain on a healthcare provider\u2014high use can mean higher revenue per patient but also greater costs, resource pressure and sensitivity to events such as disease outbreaks or changes in reimbursement.<\/p>\n
<\/p>\n
\n
\n interventional radiology
\n
\n medical
\n
\n
<\/p>\n
“bedside postpyloric feeding access, a capability previously requiring interventional radiology, with no additional clinical staffing required.”<\/p>\n
Interventional radiology is a medical specialty that uses imaging tools (like X-rays, CT scans or ultrasound) as a live map to guide tiny instruments through small skin openings to diagnose or treat problems inside the body, replacing larger surgeries. For investors, it matters because these image-guided procedures often cut recovery time, reduce hospital stays and create steady demand for specialized devices, imaging equipment and related services, affecting healthcare costs and industry revenues.<\/p>\n
<\/p>\n
\n
\n enteral feeding tube
\n
\n medical
\n
\n
<\/p>\n
“standardized protocol for bedside enteral feeding tube placement across the entire network”<\/p>\n
A flexible medical tube used to deliver nutrition, fluids or medications directly into a patient\u2019s stomach or intestines when they cannot swallow or eat normally; it can be inserted through the mouth or nose or placed through the abdominal wall. Investors care because demand for these tubes and related supplies is driven by hospital and long\u2011term care use, chronic illness and an aging population, and shifts in reimbursement, regulation or product innovation can affect manufacturers\u2019 sales much like changes in plumbing affect water delivery.<\/p>\n
<\/p>\n
\n
\n critical care
\n
\n medical
\n
\n
<\/p>\n
“Findings Published in Official Journal of the American Association of Critical Care Nurses”<\/p>\n
Critical care involves the specialized medical treatment provided to patients with life-threatening conditions that require constant monitoring and immediate intervention. It is essential for saving lives during severe health emergencies. For investors, understanding critical care highlights the importance and stability of healthcare services that support urgent and complex medical needs.<\/p>\n
<\/p>\n
AI-generated analysis. Not financial advice.<\/p>\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
<\/p>\n
![\"\"](\"https:\/\/www.stocktitan.net\/img\/icons\/Google_News_icon.svg\"){kind=icon}
<\/p>\n
See more from StockTitan in Google Search and AI answers.
\n Adds StockTitan as a preferred source \u00b7 opens Google\n <\/p>\n
\n
\n
\n
\n
\n
\n 06\/03\/2026 – 08:17 AM
\n
\n
<\/p>\n
Independent, Peer-Reviewed Study Demonstrated Significant Improvement in Patient Outcomes, Reduction in Over 350 Nursing Hours in Year One, and 20% Decrease in Repeat Imaging<\/p>\n
Validates Value of Integrating ENvue Navigation Platform as Standard of Care in U.S. Hospitals, Saving Costs on Nursing Hours, Imaging, and Patient Complications <\/p>\n
Findings Published in Official Journal of the American Association of Critical Care Nurses<\/p>\n
TYLER, Texas, June 03, 2026 (GLOBE NEWSWIRE) — ENvue Medical<\/a> (NASDAQ: FEED<\/a>) (\u201cENvue\u201d or the \u201cCompany\u201d), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that an independent, peer-reviewed study has been published in Critical Care Nurse \u2013 the official journal of the American Association of Critical Care Nurses \u2013 showing dramatic improvements in patient safety and operating cost reductions at Inova Health System, a five-hospital mid-Atlantic regional health system that adopted the ENvue\u2122 Navigation Platform.<\/p>\n \u201cThis is a landmark study demonstrating how our real-time feeding tube guidance platform significantly improves safety and enables hospitals to function more efficiently to better service their patients,\u201d said Doron Besser, MD, CEO of ENvue Medical. \u201cGiven the serious risks for both patients and hospitals, blind feeding tube placement is no longer acceptable as a standard of care. We believe data like this accelerates the clinical and institutional case for the adoption of ENvue\u2019s platform and we expect it to directly support our commercialization efforts, driving the onboarding of new hospitals and expanding our commercial footprint across health systems nationwide.\u201d<\/p>\n Titled \u201cDietitian-Led Feeding Tube Placement: Reducing Nursing Workload and Enhancing Patient Safety in the Intensive Care Unit,\u201d the study tackles one of the most consequential procedural risks in hospital intensive care units: feeding tube misplacement. Feeding tubes are traditionally inserted blindly without real-time guidance, often leading to tubes accidentally entering the airway or lungs instead of the digestive tract. This can trigger ventilator-associated pneumonia (\u201cVAP\u201d), a serious and potentially fatal lung infection. Highlighted in the study, by using ENvue\u2019s navigation technology, Inova reduced VAP cases by 67 percent and eliminated accidental insertions of feeding tubes into patients\u2019 lungs across 531 consecutive placements in its first year of use. According to studies published in ePlasty<\/a> and Medicine<\/a>, inadvertent airway placement rates are estimated at 1.2 to 3.2 percent when using blind placement techniques. Additionally, based on Agency for Healthcare Research and Quality (AHRQ) benchmarks, ENvue estimates that the reduction in VAP cases avoided over $1.5 million in hospital costs in year one.<\/p>\n Other key findings include:<\/p>\n As part of this study, the ENvue Navigation Platform was deployed across five hospitals with diverse intensive care units, including those focused on general trauma, surgical trauma, cardiovascular, medical-surgical and neurocardiovascular settings. There were no increases in clinical staffing required at any site.<\/p>\n The full study is available at https:\/\/doi.org\/10.4037\/ccn2026599<\/a>. The authors disclosed no financial relationship with ENvue Medical.<\/p>\n About ENvue Medical, Inc.<\/strong> Forward-Looking Statements<\/strong> Investor Contact:<\/strong>\n
ENvue Medical, Inc. (NASDAQ: FEED<\/a>) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:<\/p>\n\n
This press release contains \u201cforward-looking statements.\u201d Such statements may be preceded by the words \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cprojects,\u201d \u201cpredicts,\u201d \u201cestimates,\u201d \u201caims,\u201d \u201cbelieves,\u201d \u201chopes,\u201d \u201cpotential,\u201d or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical\u2019s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical\u2019s products, the success of ENvue\u2019s programs, market interest in the Company\u2019s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company\u2019s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company\u2019s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company\u2019s filings with the Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov<\/a>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.<\/p>\n
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com<\/a><\/p>\n
![\"\"](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/06\/ti.gif\"\/)
![\"\"](\"https:\/\/www.europesays.com\/ie\/wp-content\/uploads\/2026\/06\/ENvue-Medical-Inc-.png\")